ReShape reports Q3 rev $2.3M (+6.4% YoY); merger with Vyome, asset sale to Biorad for $5.16M

Vyome Holdings, Inc

Q3 revenue $2.3M, up 6.4% YoY and 16.6% sequentially; gross margin 62.8%.
Operating expenses down 40.6% in first 9 months of 2024 vs 2023.
Merger with Vyome: ReShape stockholders to own ~11.1% of combined company.
Asset sale to Biorad for $5.16M cash; includes Lap-Band, Obalon, DBSN systems.
Received Health Canada approval for Lap-Band 2.0 FLEX and $241K NIH grant.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.